Antibody Drug Conjugate News and Research

RSS

Pancreatic cancer patients may benefit from antibody-drug conjugates

Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

Astrazeneca Acquires Spirogen For Up To $440M

...

15 Oct 2013

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

...

11 Oct 2013

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

...

11 Oct 2013

ImmunoGen signs new license agreement with Novartis

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced that Novartis has licensed the exclusive right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target.

11 Oct 2013

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

Chemists at The Scripps Research Institute (TSRI) have devised a new technique for connecting drug molecules to antibodies to make advanced therapies.

8 Oct 2013

Maxim Integrated's MAX2082 octal ultrasound transceiver can save space, improve image quality

Ultrasound designers can now reduce form factor and improve image quality and reliability with the MAX2082 octal ultrasound transceiver from Maxim Integrated Products, Inc..

27 Sep 2013

Amgen Plans R&D Center In China

...

25 Sep 2013

Bayer, Broad On Five-Year Mission To Search For Novel Cancer Therapeutics

...

10 Sep 2013

Nuclea Biotechnologies Acquires Wilex' U.S. Subsidiary

...

9 Sep 2013

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Immune Pharmaceuticals Inc. announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation.

26 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company's x (IND) application has been accepted by the US FDA and is now active.

2 Aug 2013

Piramal's Healthcare invests USD 2.5 million to upgrade ADC manufacturing suites

Piramal's Healthcare vertical today announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand.

26 Jul 2013

MagnaChip announces full range of "MXsensor" product families

MagnaChip Semiconductor Corporation ("MagnaChip"), a Korean semiconductor company with a broad portfolio of analog and mixed-signal products and technologies, today announced a full range of "MXsensor" intelligent sensor product families featuring 0.18 micron mixed signal & analog technology with low power consumption.

25 Jul 2013

AbGenomics raises $9.6M for advancing therapeutic antibodies for autoimmune diseases, cancers

AbGenomics International announced today that it has raised $9.6 million in current financing round.

18 Jul 2013

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and BZL Biologics LLC, of New York, today announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.

15 Jul 2013

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Seattle Genetics, Inc. today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets.

25 Jun 2013

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Genmab A/S and ADC Therapeutics Sarl, announced today an agreement to develop a new antibody-drug conjugate product combining Genmab's HuMax-TAC antibody and ADC Therapeutics' PBD-based warhead and linker technology.

17 Jun 2013

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.

17 Jun 2013